Enanta Pharmaceuticals (ENTA) Leases (2019 - 2026)

Enanta Pharmaceuticals (ENTA) has 8 years of Leases data on file, last reported at $36.4 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 6.82% year-over-year to $36.4 million; the trailing twelve-month figure through Mar 2026 stood at $36.4 million (down 6.82% YoY), and the FY2025 full-year result was $37.5 million, down 7.65% from the prior year.
• Leases for Q1 2026 stood at $36.4 million, down from $37.0 million in the prior quarter.
• Across five years, Leases topped out at $41.2 million in Q2 2024 and bottomed at $17.2 million in Q1 2022.
• The 5-year median for Leases is $32.5 million (2024), against an average of $30.8 million.
• The widest annual swing landed in 2022, when Leases jumped 400.42%; it then fell 9.33% in 2023.
• A 5-year view of Leases shows it stood at $23.5 million in 2022, then dropped by 9.33% to $21.3 million in 2023, then jumped by 85.88% to $39.7 million in 2024, then dropped by 6.73% to $37.0 million in 2025, then slipped by 1.53% to $36.4 million in 2026.
• The last three Leases figures came in at $36.4 million (Q1 2026), $37.0 million (Q4 2025), and $37.5 million (Q3 2025), per Business Quant data.

Peer Comparison